Clinical trial
A Phase II, Randomized, Placebo-controlled Trial of the Safety, Efficacy, Pharmacodynamics and Pharmacokinetics of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A.
NCT01401257 is registered in ClinicalTrials.gov with Pharnext S.C.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Randomized, Placebo-controlled Trial of the Safety, Efficacy, Pharmacodynamics and Pharmacokinetics of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A.
- Lead sponsor
- Pharnext S.C.A.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2010
- Completion date
- December 31, 2012
- Enrollment
- 80 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
charcot-marie-tooth disease, genetic disorders, hereditary neuropathy with liability to pressure palsies